Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly reached pandemic proportions. Given that the main target of SARS-CoV-2 are lungs leading to severe pneumonia with hyperactivation of the inflammatory cascade, we conducted a prospective study to assess alveolar inflammatory status in patients with moderate to severe COVID-19. Methods Diagnostic bronchoalveolar lavage (BAL) was performed in 33 adult patients with SARS-CoV-2 infection by real-time PCR on nasopharyngeal swab admitted to the Intensive care unit (ICU) ( n = 28) and to the Intermediate Medicine Ward (IMW) ( n = 5). We analyze the differential cell count, ultrastructure of cells and Interleukin (IL)6, 8 and 10 levels. Results ICU patients showed a marked increase in neutrophils (1.24 × 10 5 ml − 1 , 0.85–2.07), lower lymphocyte (0.97 × 10 5 ml − 1 , 0.024–0.34) and macrophages fractions (0.43 × 10 5 ml − 1 , 0.34–1.62) compared to IMW patients (0.095 × 10 5 ml − 1 , 0.05–0.73; 0.47 × 10 5 ml − 1 , 0.28–1.01 and 2.14 × 10 5 ml − 1 , 1.17–3.01, respectively) ( p < 0.01). Study of ICU patients BAL by electron transmission microscopy showed viral particles inside mononuclear cells confirmed by immunostaining with anti-viral capsid and spike antibodies. IL6 and IL8 were significantly higher in ICU patients than in IMW (IL6 p < 0.01, IL8 p < 0.0001), and also in patients who did not survive (IL6 p < 0.05, IL8 p = 0.05 vs. survivors). IL10 did not show a significant variation between groups. Dividing patients by treatment received, lower BAL concentrations of IL6 were found in patients treated with steroids as compared to those treated with tocilizumab ( p < 0.1) or antivirals ( p < 0.05). Conclusions Alveolitis, associated with COVID-19, is mainly sustained by innate effectors which showed features of extensive activation. The burden of pro-inflammatory cytokines IL6 and IL8 in the broncho-alveolar environment is associated with clinical outcome. Supplementary Information The online version contains supplementary material available at 10.1186/s12890-020-01343-z.
【저자키워드】 COVID-19, SARS-CoV-2, Cytokines, lung, Bronchoalveolar lavage, 【초록키워드】 Treatment, antibodies, Macrophage, coronavirus, pandemic, severe COVID-19, Antiviral, Tocilizumab, Prospective Study, Variation, neutrophil, Infection, IL6, Transmission, ICU, Anti-viral, Clinical outcome, Medicine, Nasopharyngeal swab, BAL, lymphocyte, interleukin, Survivors, Real-time PCR, Microscopy, Patient, severe pneumonia, ultrastructure, Care, Concentration, immunostaining, steroid, mononuclear cell, acute respiratory syndrome, Activation, supplementary material, proportions, ward, fraction, pro-inflammatory cytokine, cell count, Hyperactivation, IL10, effector, intermediate, viral particle, inflammatory status, alveolar, inflammatory cascade, alveolitis, feature, Cell, ICU patient, Result, conducted, was performed, treated, IL8, increase in, significantly higher, reached, groups, sustained, patients treated, patients with moderate, patients with SARS-CoV-2, with COVID-19, 【제목키워드】 Inflammation, Clinical outcome, correlation,